A risk score can be used to predict survival in patients with primary sclerosing cholangitis. This can aid in patient counseling and in making therapeutic decisions such as transplant timing. The study was done through a collaboration of the Mayo Clinic, John Radcliffe Hospital in Oxford, New England Medical Center, University of Texas Southwestern Medical Center, and King's College Hospital in London.
Parameters:
(1) serum total bilirubin in mg/dL
(2) age in years
(3) histologic stage
(4) splenomegaly
Parameter |
Finding |
Points |
histologic stage |
I |
1 |
|
II |
2 |
|
III |
3 |
|
IV |
4 |
splenomegaly |
absent |
0 |
|
present |
1 |
risk score =
= (0.535 * (LN(serum total bilirubin in mg/dL))) + (0.486 * (histologic stage)) + (0.041 * (age in years)) + (0.705 * (points for splenomegaly))
where:
• LN indicates natural logarithm (base e)
• An histologic stage is graded as the higher level (for example: stage 3-4 is scored as 4).
Interpretation
probability of surviving X years =
= S(X)^(EXP((risk score) – 3.326))
where:
• 3.326 is the risk score for the average patient in the data set
Survival in Years |
S(t) |
1 |
0.951 |
2 |
0.915 |
3 |
0.871 |
4 |
0.844 |
5 |
0.779 |
6 |
0.752 |
7 |
0.741 |
(from Table 5, page 1897)
Purpose: To estimate the survival for a patient with primary sclerosing cholangitis using the Multicenter risk score.
Specialty: Gastroenterology, Immunology/Rheumatology
Objective: risk factors, other testing, severity, prognosis, stage, options
ICD-10: K83.0, Z94.4, K74.3,